1. Home
  2. AKRO vs HDL Comparison

AKRO vs HDL Comparison

Compare AKRO & HDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • HDL
  • Stock Information
  • Founded
  • AKRO 2017
  • HDL 2016
  • Country
  • AKRO United States
  • HDL Singapore
  • Employees
  • AKRO N/A
  • HDL N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • HDL Restaurants
  • Sector
  • AKRO Health Care
  • HDL Consumer Discretionary
  • Exchange
  • AKRO Nasdaq
  • HDL Nasdaq
  • Market Cap
  • AKRO 3.9B
  • HDL 1.2B
  • IPO Year
  • AKRO 2019
  • HDL 2024
  • Fundamental
  • Price
  • AKRO $51.77
  • HDL $19.22
  • Analyst Decision
  • AKRO Strong Buy
  • HDL
  • Analyst Count
  • AKRO 6
  • HDL 0
  • Target Price
  • AKRO $82.50
  • HDL N/A
  • AVG Volume (30 Days)
  • AKRO 1.7M
  • HDL 2.4K
  • Earning Date
  • AKRO 08-08-2025
  • HDL 08-26-2025
  • Dividend Yield
  • AKRO N/A
  • HDL N/A
  • EPS Growth
  • AKRO N/A
  • HDL 110.82
  • EPS
  • AKRO N/A
  • HDL 0.06
  • Revenue
  • AKRO N/A
  • HDL $789,766,000.00
  • Revenue This Year
  • AKRO N/A
  • HDL $17.95
  • Revenue Next Year
  • AKRO N/A
  • HDL $13.32
  • P/E Ratio
  • AKRO N/A
  • HDL $33.62
  • Revenue Growth
  • AKRO N/A
  • HDL 10.91
  • 52 Week Low
  • AKRO $21.02
  • HDL $13.94
  • 52 Week High
  • AKRO $58.40
  • HDL $30.00
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 49.14
  • HDL N/A
  • Support Level
  • AKRO $51.08
  • HDL N/A
  • Resistance Level
  • AKRO $57.35
  • HDL N/A
  • Average True Range (ATR)
  • AKRO 2.21
  • HDL 0.00
  • MACD
  • AKRO -0.81
  • HDL 0.00
  • Stochastic Oscillator
  • AKRO 11.08
  • HDL 0.00

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. It mission is to become a global integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.

Share on Social Networks: